Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy

Totsune, Kazuhito; Takahashi, Kazuhiro; Arihara, Zenei; Sone, Masahiko; Murakami, Osamu; Ito, Sadayoshi; Kikuya, Masahiro; Ohkubo, Takayoshi; Hashimoto, Junichiro; Imai, Yutaka

doi:10.1016/j.peptides.2004.06.024

Cited by 93 publications

(74 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We measured circulating plasma UTS in the SD rat in the low pmol range (Song et al 2006) and therefore have used bolus and continuous infusions of UTS in the low pmol/100 g body weight range to effect manipulations within a physiologically relevant range. In the present study, this resulted in a twofold increase in urinary UTS concentration at the highest dose employed; a similar increase in urinary UTS concentration has been reported in patients with renal disease (Totsune et al 2004). Previous clearance studies in rats have injected bolus doses systemically at 1-100 nmol/kg (Ovcharenko et al 2006) or infused at 2 .…”

Section: Discussionsupporting

confidence: 86%

Renal haemodynamic and tubular actions of urotensin II in the rat

Abdel-Razik¹,

Forty²,

Balment³

et al. 2008

Journal of Endocrinology

View full text Add to dashboard Cite

Urotensin II (UTS) is a potent vasoactive peptide that was originally identified in teleost fish. Mammalian orthologues of UTS and its receptor (UTSR) have been described in several species, including humans and rats. We have shown previously that bolus injections of UTS caused a decrease in urine flow and sodium excretion rates in parallel with marked reductions in renal blood flow (RBF) and glomerular filtration rate (GFR). The aim of this study was to determine the effect of UTS infusion at a dose that has minimal impact upon renal haemodynamics in order to identify a potential direct tubular action of UTS. Infusion of rat UTS (rUTS) at 0 . 6 pmol/min per 100 g body weight in male Sprague-Dawley rats, which had no effect on RBF and caused a 30% reduction in GFR, resulted in a significant increase in the fractional excretion of sodium (vehicle 2 . 3G0 . 6 versus rUTS 0 . 6 pmol 4 . 5G0 . 6%, P!0 . 05) and potassium. At the higher dose of 6 pmol/min per 100 g body weight, haemodynamic effects dominated the response. rUTS induced a marked reduction in RBF and GFR (vehicle 1 . 03G 0 . 06 versus rUTS 6 pmol 0 . 31G0 . 05 ml/min per 100 g body weight, P!0 . 05) resulting in an anti-diuresis and antinatriuresis, but no change in fractional excretion of sodium or potassium. Uts2d and Uts2r mRNA expression were greater in the renal medulla compared with the cortex. Together, these data support an inhibitory action of Uts2d on renal tubule sodium and potassium reabsorption in the rat, in addition to its previously described renal haemodynamic effects.

show abstract

Section: Discussionsupporting

confidence: 86%

Renal haemodynamic and tubular actions of urotensin II in the rat

Abdel-Razik¹,

Forty²,

Balment³

et al. 2008

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Plasma UII/URP concentrations are in the same range in human (2.5-24 fmol/ml; Totsune et al, 2004), rat (2.9 fmol/ml; Prosser et al, 2006), sucker (40 fmol/ml; Kobayashi et al, 1986), goldfish Carassius auratus (16 fmol/ml; Kobayashi et al, 1986), and flounder (5-8 fmol/ml; Lu et al, 2006).…”

Section: H Distribution Of Urotensin II and Urotensin Ii-related Pepmentioning

confidence: 82%

International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

et al. 2014

View full text Add to dashboard Cite

“…Patients with hypertensive renal disease displayed an increased urinary UII-like immunoreactivity compared with normotensive renal disease patients, perhaps as a result of hypertensive target organ damage (87). Renal dysfunction in diabetes is associated with higher plasma and urinary levels of UII than in diabetics with normal renal function (128). UII and UT receptor mRNA is increased in renal biopsy tissue of patients with diabetic nephropathy compared with normal subjects by upward of 45-to 2,000-fold (69).…”

Section: Pathological Significance Of Uiimentioning

confidence: 99%

Role of urotensin II in health and disease

Ross

McKendy

Giaid

2010

American Journal of Physiology-Regulatory, Integrative and Comp

128

107

View full text Add to dashboard Cite

Urotensin II (UII) is an 11 amino acid cyclic peptide originally isolated from the goby fish. The amino acid sequence of UII is exceptionally conserved across most vertebrate taxa, sharing structural similarity to somatostatin. UII binds to a class of G protein-coupled receptor known as GPR14 or the urotensin receptor (UT). UII and its receptor, UT, are widely expressed throughout the cardiovascular, pulmonary, central nervous, renal, and metabolic systems. UII is generally agreed to be the most potent endogenous vasoconstrictor discovered to date. Its physiological mechanisms are similar in some ways to other potent mediators, such as endothelin-1. For example, both compounds elicit a strong vascular smooth muscle-dependent vasoconstriction via Ca 2ϩ release. UII also exerts a wide range of actions in other systems, such as proliferation of vascular smooth muscle cells, fibroblasts, and cancer cells. It also 1) enhances foam cell formation, chemotaxis of inflammatory cells, and inotropic and hypertrophic effects on heart muscle; 2) inhibits insulin release, modulates glomerular filtration, and release of catecholamines; and 3) may help regulate food intake and the sleep cycle. Elevated plasma levels of UII and increased levels of UII and UT expression have been demonstrated in numerous diseased conditions, including hypertension, atherosclerosis, heart failure, pulmonary hypertension, diabetes, renal failure, and the metabolic syndrome. Indeed, some of these reports suggest that UII is a marker of disease activity. As such, the UT receptor is emerging as a promising target for therapeutic intervention. Here, a concise review is given on the vast physiologic and pathologic roles of UII.UT receptor; somatostatin; human; experimental animals; autocrine/paracrine UROTENSIN II (UII) was initially isolated from the urophysis of the goby fish (Gillichthys mirabilis) (97). The peptide was subsequently isolated from the white sucker (Catostomus commersoni) and the carp (Cyprinus carpio). Although there were variations in the amino acid sequence near the amino terminus, in both species the UII molecule retained the COOH-terminal cyclic sequence: -Cys

show abstract

Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy

Cited by 93 publications

References 24 publications

Renal haemodynamic and tubular actions of urotensin II in the rat

Renal haemodynamic and tubular actions of urotensin II in the rat

International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

Role of urotensin II in health and disease

Contact Info

Product

Resources

About